Bank of Nova Scotia Acquires 21,822 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Bank of Nova Scotia boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHRFree Report) by 713.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,879 shares of the biotechnology company’s stock after acquiring an additional 21,822 shares during the quarter. Bank of Nova Scotia owned 0.05% of United Therapeutics worth $5,470,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in UTHR. Victory Capital Management Inc. grew its holdings in United Therapeutics by 44.9% during the 3rd quarter. Victory Capital Management Inc. now owns 32,743 shares of the biotechnology company’s stock worth $7,396,000 after acquiring an additional 10,140 shares during the last quarter. Jump Financial LLC bought a new stake in United Therapeutics during the 3rd quarter worth approximately $251,000. Great Lakes Advisors LLC bought a new stake in United Therapeutics during the 3rd quarter worth approximately $233,000. New York Life Investment Management LLC grew its holdings in United Therapeutics by 90.8% during the 3rd quarter. New York Life Investment Management LLC now owns 5,406 shares of the biotechnology company’s stock worth $1,221,000 after acquiring an additional 2,573 shares during the last quarter. Finally, J.P. Morgan Private Wealth Advisors LLC grew its holdings in United Therapeutics by 6.1% during the 3rd quarter. J.P. Morgan Private Wealth Advisors LLC now owns 1,275 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 73 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Christopher Causey sold 2,240 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the sale, the director now owns 4,185 shares in the company, valued at approximately $1,087,723.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other United Therapeutics news, Director Christopher Causey sold 2,240 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the sale, the director now owns 4,185 shares in the company, valued at approximately $1,087,723.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Martine A. Rothblatt sold 1,468 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $275.85, for a total transaction of $404,947.80. Following the completion of the sale, the director now owns 130 shares of the company’s stock, valued at approximately $35,860.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 164,328 shares of company stock worth $40,002,673. 12.50% of the stock is owned by corporate insiders.

United Therapeutics Stock Down 1.1 %

United Therapeutics stock opened at $273.19 on Wednesday. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $280.00. The firm’s fifty day moving average is $251.85 and its 200 day moving average is $236.34. The company has a market capitalization of $12.12 billion, a PE ratio of 12.92, a PEG ratio of 4.11 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHRGet Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The business had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. United Therapeutics’s quarterly revenue was up 33.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.86 EPS. As a group, sell-side analysts predict that United Therapeutics Co. will post 24.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on UTHR. Oppenheimer boosted their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research report on Thursday, March 7th. HC Wainwright restated a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. Wedbush restated an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. Finally, The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $309.44.

Get Our Latest Stock Report on UTHR

United Therapeutics Profile

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.